AJP - Endocrinology and Metabolism, Vol 258, Issue 1 E40-E45, Copyright © 1990 by American Physiological Society

ARTICLES

Cholecystokinin receptors and vagal nerves in control of food intake in rats

J. Garlicki, P. K. Konturek, J. Majka, N. Kwiecien and S. J. Konturek
Institute of Physiology, Academy of Medicine, Krakow, Poland.

This study was designed to determine the specificity and physiological nature of short-term satiety effects of cholecystokinin (CCK) in rats with intact and transected vagal nerves. Rats with-the gastric fistulas, closed or open, were used for normal feeding or sham feeding of liquid meal offered for 30 min. CCK-8 (0.5-10 nmol/kg) injected intraperitoneally (ip) 15 min before feeding inhibited food intake dose dependently in both normal-fed and sham-fed rats at a minimal inhibitory dose of 1 nmol/kg. CCK-8 at the same doses caused a potent stimulation of pancreatic protein secretion, reaching maximum at a dose of approximately 0.5 nmol/kg. Pretreatment with a potent CCK receptor antagonist, L-364,718 (2.5 mg/kg ip), increased food intake during normal feeding (but not sham feeding) and almost completely blocked the satiety and pancreatic stimulatory effects of CCK. When feeding was preceded by intragastric administration of proteinase inhibitor (Foy-305, 200 mg/kg), food preload, or diversion of bile-pancreatic secretion to the exterior, there was a significant increase in the plasma level of CCK and an inhibition of food intake by about 36, 78, and 25%, respectively. Pretreatment with L-364,718 completely abolished this inhibition by Foy-305 and bile-pancreatic diversion and reduced that caused by food preload. Among other gut peptides given ip (10 nmol/kg) only bombesin reduced food intake, whereas gastrin, secretin, gastric inhibitory polypeptide (GIP), pancreatic polypeptide (PP), and peptide YY (PYY) were ineffective.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				C. O'Mahony, H. van der Kleij, J. Bienenstock, F. Shanahan, and L. O'Mahony Loss of vagal anti-inflammatory effect: in vivo visualization and adoptive transfer Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2009; 297(4): R1118 - R1126. [Abstract] [Full Text] [PDF]

				H. van der Kleij, C. O'Mahony, F. Shanahan, L. O'Mahony, and J. Bienenstock Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2008; 295(4): R1131 - R1137. [Abstract] [Full Text] [PDF]

				J. Glatzle, M. E. Kreis, K. Kawano, H. E. Raybould, and T. T. Zittel Postprandial neuronal activation in the nucleus of the solitary tract is partly mediated by CCK-A receptors Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2001; 281(1): R222 - R229. [Abstract] [Full Text] [PDF]

				C. G MacIntosh, J. M Andrews, K. L Jones, J. M Wishart, H. A Morris, J. B. Jansen, J. E Morley, M. Horowitz, and I. M Chapman Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility Am. J. Clinical Nutrition, May 1, 1999; 69(5): 999 - 1006. [Abstract] [Full Text] [PDF]

				E. Bignon, R. Alonso, M. Arnone, R. Boigegrain, R. Brodin, C. Gueudet, M. Héaulme, P. Keane, M. Landi, J.-C. Molimard, et al. SR146131: A New Potent, Orally Active, and Selective Nonpeptide Cholecystokinin Subtype 1 Receptor Agonist. II: In Vivo Pharmacological Characterization J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 752 - 761. [Abstract] [Full Text]